Table 1 Patient characteristics and treatment response (actual response to Peg-interferon + ribavirin or expected response after addition of directly acting antivirals)

Qualitative variables

Gender:

  Males (%)

37

(48)

6

(22)

43

(41)

  Females (%)

40

(52)

21

(78)

61

(59)

Genotype:

  1b (%)

60

(78)

16

(59)

76

(73)

  1a (%)

11

(14)

10

(37)

21

(20)

  1 (%)

6

(8)

1

(4)

7

(7)

RVR with PEG-IFN/RBV:

  nonSVR RVR (%)

2

(3)

0

(0)

2

(2)

  SVR RVR (%)

5

(6)

2

(8)

7

(7)

  SVR nonRVR (%)

41

(53)

9

(33)

50

(48)

  nonSVR nonRVR (%)

39

(38)

16

(59)

45

(43)

Response to PEG-INF/RBV (actual):

  SVR (%)

46

(60)

11

(41)

57

(55)

  Relapsers (%)

12

(15)

4

(15)

16

(15)

  Partials (%)

2

(3)

4

(15)

6

(6)

  Nulls (%)

17

(22)

8

(29)

25

(24)

Response to PEG-INF/RBV + DAA in naïves (estimated):

  SVR (%)

58

(75)

20

(75)

78

(75)

  Non response (%)

19

(25)

7

(25)

26

(25)

Response to PEG-IFN/RBV in naïves plus PEG-IFN/RBV + DAA in non responders (estimated):

  SVR (%)

62

(81)

19

(70)

81

(78)

  Non response (%)

15

(19)

8

(30)

23

(22)

Quantitative variables

Age (at PEG-IFN/RBV start):

  Median

50

45

47

  Range

20-70

36-60

20-70

  IQR

23

7

17

  Standard Deviation

14

5

12

Duration of PEG-IFN/RBV treatment in weeks (actual):

  Mean

44

40

42